Nicotinamide Riboside: A Promising Treatment for Type 1 Cardiorenal Syndrome in Myocardial Infarction‐Induced Acute Kidney Injury by Upregulating Nicotinamide Phosphoribosyltransferase‐Mediated Nicotinamide Dinucleotide Levels

BACKGROUND: , takes place in the heart after MI, but the impact on kidney NAD metabolism and function has not been addressed before. METHODS AND RESULTS: MI was induced by ligating the left anterior descending coronary artery in 2-month-old C57BL6/J mice, followed by the administration of NR (IP injection, 400 mg/kg per day) for 4 and 7 days. We hypothesized that NR treatment could be a potentially promising therapy for MI-induced acute kidney injury. Our findings showed no significant improvement in cardiac ejection fraction following NR treatment at days 4 and 7 post-MI, whereas kidney functions were enhanced and morphological alterations and cell death decreased. The observed renal protection seems to be mediated by an upregulation of NAMPT-mediated increase in renal NAD levels, notably in the distal tubules. CONCLUSIONS: Our findings indicate that NR could potentially be a promising therapy for acute kidney injury following an early stage of MI.